Skip to main content
Clinical Trials/CTRI/2025/09/095340
CTRI/2025/09/095340Not yet recruitingNot Applicable

The role of individualised homoeopathic medicines in improving the quality of life in dementia

WHITE MEMORIAL HOMOEO MEDICAL COLLEGE AND HOSPITAL1 site in 1 country40 target enrollmentStarted: October 13, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
Quality of life will be assessed by using Dementia Quality of Life.

Study Overview

Brief Summary

AIM:

To evaluate the effectiveness of individualized Homoeopathic medicines inimprovingthe quality of life indementiapatients.

OBJECTIVES

To assess the impact of individualized Homoeopathic medicine on the quality of life in dementia patients.

To measure the changes in memory, emotional wellbeing, daily activities using DEMQOL questionnaire before and after treatment

To identify the most used Homoeopathic medicines for dementia

BACKGROUND AND JUSTIFICATION

Dementia is a progressive neurodegenerative disorder marked by a decline in cognitive function, memory, language, and the ability to perform everyday activities. It primarily affects the elderly population and is associated with a significant deterioration in quality of life both for the individual and their caregivers .Despite the availability of conventional pharmacological treatments, these often provide only symptomatic relief and are frequently accompanied by side effects, especially in elderly individuals with multiple comorbidities. While there is small scale studies have reported improvement in symptoms and over all wellbeing in dementia patients using individualized homoeopathic medicine, there is a lack of structured clinical evidence evaluating its impact on quality of life using validated scale like DEMQOL. This study aim to play a role on improving overall wellbeing in dementia patients.

METHODOLOGY

The study will be conducted with clinically diagnosed 40 cases of dementia will be selected based on inclusion and exclusion criteria for the study. Diagnostic screening will be done by Montreal Cognitive Assessment. The cases will be analyzed and the totality of symptoms will be erected based on Homoeopathic philosophy to arrive the suitable remedy for each patient. Then the individualized Homoeopathic medicine will be prescribed with the proper dose, potency, and repetitions. Follow up will be taken once in a month to assess the improvement in quality of life among dementia patients. Pre assessment and post assessment of Dementia Quality of Life DEMQOL will be taken three months once to evaluate the quality of life in dementia patients.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
46.00 Year(s) to 80.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Age of the patient above 45 years.
  • Confirmed cases of dementia through Montreal Cognitive assessment.
  • Patient having MoCA score above 10 to 25.

Exclusion Criteria

  • Patients having other neurological disorders like Alzheimer disease, Parkinsons disease.
  • Patients having other psychiatric illness like, Bipolar disorder, Schizophrenia etc.
  • Patients under allopathic medication such as anticholinergic and antipsychotic drugs Patients having serious systemic disorders.

Outcomes

Primary Outcomes

Quality of life will be assessed by using Dementia Quality of Life.

Time Frame: 3 months

Maximum score- 112

Time Frame: 3 months

From baseline score: 1 to 9 score increases - Mild improvement.

Time Frame: 3 months

10–19 score increases - Moderate improvement.

Time Frame: 3 months

More than 20 score increases - Marked improvement

Time Frame: 3 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
WHITE MEMORIAL HOMOEO MEDICAL COLLEGE AND HOSPITAL
Sponsor Class
Private medical college
Responsible Party
Principal Investigator
Principal Investigator

Dr KALAIYARASI P

WHITE MEMORIAL HOMOEO MEDICAL COLLEGE AND HOSPITAL

Study Sites (1)

Loading locations...

Similar Trials